Hemato Oncology Testing Market by Type of Cancerand Application- Global Industry Analysis & Forecast to 2027
Published On : November 2020 Pages : 180 Category: Pharma & Healthcare Report Code : HC1113627
Hemato Oncology Testing Market By Type of Cancer (Leukemia and Non-Hodgkin’s Lymphoma) and Application (Clinical laboratories, Hospitals, Academic & Research Institutes, Other)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Hemato Oncology Testing Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Hemato Oncology is thecombined medical practice of hematology (the study of the blood’s physiology) and oncology (the study of cancer). This type of medicine diagnoses and treats cancerous blood disorders and cancers, and manages symptoms of these diseases and resultant tumors.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Hemato Oncology Testing Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Asuragen, Inc.
- Abbott Laboratories
- MolecularMD
- ARUP Laboratories Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Adaptive Biotechnologies
- Thermo Fisher Scientific, Inc.,
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Hemato Oncology Testing Market, ByType of Cancer, Estimates and Forecast, 2017-2027 ($Million)
o Leukemia
o Non-Hodgkin’s Lymphoma
· Hemato Oncology Testing Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Clinical laboratories
o Hospitals
o Academic & Research Institutes
o Other
· Hemato Oncology Testing Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Asuragen, Inc.
o Abbott Laboratories
o MolecularMD
o ARUP Laboratories Inc.
o F. Hoffmann-La Roche Ltd.
o QIAGEN N.V.
o Adaptive Biotechnologies
o Thermo Fisher Scientific, Inc.,
· Hemato Oncology Testing Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Hemato Oncology Testing Market, By Country
o U.S. Hemato Oncology Testing Market
o Canada Hemato Oncology Testing Market
o Mexico Hemato Oncology Testing Market
o Europe
§ Europe Hemato Oncology Testing Market, By Country
o UK Hemato Oncology Testing Market
o Germany Hemato Oncology Testing Market
o France Hemato Oncology Testing Market
o Russia Hemato Oncology Testing Market
o Italy Hemato Oncology Testing Market
o Rest of Europe Hemato Oncology Testing Market
o Asia-Pacific
§ Asia-Pacific Hemato Oncology Testing Market, By Country
o China Hemato Oncology Testing Market
o Japan Hemato Oncology Testing Market
o South Korea Hemato Oncology Testing Market
o India Hemato Oncology Testing Market
o Southeast Asia Hemato Oncology Testing Market
o Rest of Asia-Pacific Hemato Oncology Testing Market
o South America
§ South America Hemato Oncology Testing Market
o Brazil Hemato Oncology Testing Market
o Argentina Hemato Oncology Testing Market
o Columbia Hemato Oncology Testing Market
o Rest of South America Hemato Oncology Testing Market
o Middle East and Africa
§ Middle East and Africa Hemato Oncology Testing Market
o Saudi Arabia Hemato Oncology Testing Market
o UAE Hemato Oncology Testing Market
o Egypt Hemato Oncology Testing Market
o Nigeria Hemato Oncology Testing Market
o South Africa Hemato Oncology Testing Market
o TurkeyHemato Oncology Testing Market
o Rest of MEA Hemato Oncology Testing Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Hemato Oncology Testing Market, By Type Of Cancer
5.1. Introduction
5.2. Global Hemato Oncology Testing Revenue and Market Share by Type Of Cancer (2017-2021)
5.2.1. Global Hemato Oncology Testing Revenue and Revenue Share by Type Of Cancer (2017-2021)
5.3. Leukemia
5.3.1. Global Leukemia Revenue and Growth Rate (2017-2021)
5.4. Non-Hodgkin’s Lymphoma
5.4.1. Global Non-Hodgkin’s Lymphoma Revenue and Growth Rate (2017-2021)
6. Hemato Oncology Testing Market, By Applications
6.1. Introduction
6.2. Global Hemato Oncology Testing Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Hemato Oncology Testing Revenue and Revenue Share by Applications (2017-2021)
6.3. Clinical laboratories
6.3.1. Global Clinical laboratories Revenue and Growth Rate (2017-2021)
6.4. Hospitals
6.4.1. Global Hospitals Revenue and Growth Rate (2017-2021)
6.5. Academic & Research Institutes
6.5.1. Global Academic & Research Institutes Revenue and Growth Rate (2017-2021)
6.6. Other
6.6.1. Global Other Revenue and Growth Rate (2017-2021)
7. Hemato Oncology Testing Market, By Region
7.1. Introduction
7.2. Global Hemato Oncology Testing Revenue and Market Share by Regions
7.2.1. Global Hemato Oncology Testing Revenue by Regions (2017-2021)
7.3. North America Hemato Oncology Testing by Countries
7.3.1. North America Hemato Oncology Testing Revenue and Growth Rate (2017-2021)
7.3.2. North America Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Hemato Oncology Testing by Countries
7.4.1. Europe Hemato Oncology Testing Revenue and Growth Rate (2017-2021)
7.4.2. Europe Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Hemato Oncology Testing by Countries
7.5.1. Asia-Pacific Hemato Oncology Testing Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Hemato Oncology Testing by Countries
7.6.1. South America Hemato Oncology Testing Revenue and Growth Rate (2017-2021)
7.6.2. South America Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Hemato Oncology Testing by Countries
7.7.1. Middle East and Africa Hemato Oncology Testing Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Asuragen, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Abbott Laboratories
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. MolecularMD
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. ARUP Laboratories Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. QIAGEN N.V.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Adaptive Biotechnologies
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Thermo Fisher Scientific, Inc.,
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
9. Hemato Oncology Testing Market Forecast (2022-2027)
9.1. Global Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Hemato Oncology Testing Market Forecast by Regions (2022-2027)
9.2.1. North America Hemato Oncology Testing Market Forecast (2022-2027)
9.2.1.1. United States Hemato Oncology Testing Market Forecast (2022-2027)
9.2.1.2. Canada Hemato Oncology Testing Market Forecast (2022-2027)
9.2.1.3. Mexico Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2. Europe Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.1. Germany Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.2. France Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.3. UK Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.4. Russia Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.5. Italy Hemato Oncology Testing Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3. Asia-Pacific Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.1. China Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.2. Japan Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.3. Korea Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.4. India Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Hemato Oncology Testing Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Hemato Oncology Testing Market Forecast (2022-2027)
9.2.4. South America Hemato Oncology Testing Market Forecast (2022-2027)
9.2.4.1. Brazil Hemato Oncology Testing Market Forecast (2022-2027)
9.2.4.2. Argentina Hemato Oncology Testing Market Forecast (2022-2027)
9.2.4.3. Columbia Hemato Oncology Testing Market Forecast (2022-2027)
9.2.4.4. Rest of South America Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5. Middle East and Africa Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.3. Egypt Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.4. Nigeria Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.5. South Africa Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.6. Turkey Hemato Oncology Testing Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Hemato Oncology Testing Market Forecast (2022-2027)
9.3. Hemato Oncology Testing Market Forecast by Type Of Cancer (2022-2027)
9.3.1. Hemato Oncology Testing Forecast by Type Of Cancer (2022-2027)
9.3.2. Hemato Oncology Testing Market Share Forecast by Type Of Cancer (2022-2027)
9.4. Hemato Oncology Testing Market Forecast by Applications (2022-2027)
9.4.1. Hemato Oncology Testing Forecast by Applications (2022-2027)
9.4.2. Hemato Oncology Testing Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Hemato Oncology Testing Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Hemato Oncology Testing Revenue and Revenue Share by Type Of Cancer (2017-2019)
Figure Global Leukemia Revenue and Growth Rate (2017-2019)
Figure Global Non-Hodgkin’s Lymphoma Revenue and Growth Rate (2017-2019)
Table Global Hemato Oncology Testing Revenue and Revenue Share by Applications (2017-2019)
Figure Global Clinical laboratories Revenue and Growth Rate (2017-2019)
Figure Global Hospitals Revenue and Growth Rate (2017-2019)
Figure Global Academic & Research Institutes Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Hemato Oncology Testing Revenue by Regions (2017-2019)
Figure North America Hemato Oncology Testing Growth Rate (2017-2019)
Figure North America Hemato Oncology Testing Revenue and Growth Rate (2017-2019)
Figure North America Hemato Oncology Testing by Countries (2017-2019)
Figure North America Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2019)
Figure United States Hemato Oncology Testing Growth Rate (2017-2019)
Figure United States Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Hemato Oncology Testing Growth Rate (2017-2019)
Figure Canada Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Hemato Oncology Testing Growth Rate (2017-2019)
Figure Mexico Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Hemato Oncology Testing Growth Rate (2017-2019)
Figure Europe Hemato Oncology Testing Revenue and Growth Rate (2017-2019)
Figure Europe Hemato Oncology Testing by Countries (2017-2019)
Figure Europe Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2019)
Figure Germany Hemato Oncology Testing Growth Rate (2017-2019)
Figure Germany Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Hemato Oncology Testing Growth Rate (2017-2019)
Figure France Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Hemato Oncology Testing Growth Rate (2017-2019)
Figure UK Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Hemato Oncology Testing Growth Rate (2017-2019)
Figure Russia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Hemato Oncology Testing Growth Rate (2017-2019)
Figure Italy Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Hemato Oncology Testing Growth Rate (2017-2019)
Figure Rest of Europe Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Hemato Oncology Testing Growth Rate (2017-2019)
Figure Asia-Pacific Hemato Oncology Testing Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Hemato Oncology Testing by Countries (2017-2019)
Figure Asia-Pacific Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2019)
Figure China Hemato Oncology Testing Growth Rate (2017-2019)
Figure China Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Hemato Oncology Testing Growth Rate (2017-2019)
Figure Japan Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Hemato Oncology Testing Growth Rate (2017-2019)
Figure Korea Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Hemato Oncology Testing Growth Rate (2017-2019)
Figure India Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Hemato Oncology Testing Growth Rate (2017-2019)
Figure Southeast Asia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Hemato Oncology Testing Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Hemato Oncology Testing Growth Rate (2017-2019)
Figure South America Hemato Oncology Testing Revenue and Growth Rate (2017-2019)
Figure South America Hemato Oncology Testing by Countries (2017-2019)
Figure South America Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Hemato Oncology Testing Growth Rate (2017-2019)
Figure Brazil Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Hemato Oncology Testing Growth Rate (2017-2019)
Figure Argentina Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Hemato Oncology Testing Growth Rate (2017-2019)
Figure Columbia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Hemato Oncology Testing Growth Rate (2017-2019)
Figure Rest of South America Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Hemato Oncology Testing Growth Rate (2017-2019)
Figure Middle East and Africa Hemato Oncology Testing Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Hemato Oncology Testing by Countries (2017-2019)
Figure Middle East and Africa Hemato Oncology Testing Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Hemato Oncology Testing Growth Rate (2017-2019)
Figure Saudi Arabia Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Hemato Oncology Testing Growth Rate (2017-2019)
Figure United Arab Emirates Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Hemato Oncology Testing Growth Rate (2017-2019)
Figure Egypt Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Hemato Oncology Testing Growth Rate (2017-2019)
Figure Nigeria Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Hemato Oncology Testing Growth Rate (2017-2019)
Figure South Africa Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Hemato Oncology Testing Growth Rate (2017-2019)
Figure Turkey Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Hemato Oncology Testing Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2017-2019)
Table Asuragen, Inc. Hemato Oncology Testing Financial Overview
Table Abbott Laboratories Hemato Oncology Testing Financial Overview
Table MolecularMD Hemato Oncology Testing Financial Overview
Table ARUP Laboratories Inc. Hemato Oncology Testing Financial Overview
Table F. Hoffmann-La Roche Ltd. Hemato Oncology Testing Financial Overview
Table QIAGEN N.V. Hemato Oncology Testing Financial Overview
Table Adaptive Biotechnologies Hemato Oncology Testing Financial Overview
Table Thermo Fisher Scientific, Inc., Hemato Oncology Testing Financial Overview
Figure Global Hemato Oncology Testing Revenue (Millions USD) and Growth Rate (2019-2027)
Table Hemato Oncology Testing Market Forecast by Regions (2019-2027)
Figure North America Hemato Oncology Testing Market Forecast (2019-2027)
Figure United States Hemato Oncology Testing Market Forecast (2019-2027)
Figure Canada Hemato Oncology Testing Market Forecast (2019-2027)
Figure Mexico Hemato Oncology Testing Market Forecast (2019-2027)
Figure Europe Hemato Oncology Testing Market Forecast (2019-2027)
Figure Germany Hemato Oncology Testing Market Forecast (2019-2027)
Figure France Hemato Oncology Testing Market Forecast (2019-2027)
Figure UK Hemato Oncology Testing Market Forecast (2019-2027)
Figure Russia Hemato Oncology Testing Market Forecast (2019-2027)
Figure Italy Hemato Oncology Testing Market Forecast (2019-2027)
Figure Rest of Europe Hemato Oncology Testing Market Forecast (2019-2027)
Figure Asia-Pacific Hemato Oncology Testing Market Forecast (2019-2027)
Figure China Hemato Oncology Testing Market Forecast (2019-2027)
Figure Japan Hemato Oncology Testing Market Forecast (2019-2027)
Figure Korea Hemato Oncology Testing Market Forecast (2019-2027)
Figure India Hemato Oncology Testing Market Forecast (2019-2027)
Figure Southeast Asia Hemato Oncology Testing Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Hemato Oncology Testing Market Forecast (2019-2027)
Figure South America Hemato Oncology Testing Market Forecast (2019-2027)
Figure Brazil Hemato Oncology Testing Market Forecast (2019-2027)
Figure Argentina Hemato Oncology Testing Market Forecast (2019-2027)
Figure Columbia Hemato Oncology Testing Market Forecast (2019-2027)
Figure Rest of South America Hemato Oncology Testing Market Forecast (2019-2027)
Figure Middle East and Africa Hemato Oncology Testing Market Forecast (2019-2027)
Figure Saudi Arabia Hemato Oncology Testing Market Forecast (2019-2027)
Figure United Arab Emirates Hemato Oncology Testing Market Forecast (2019-2027)
Figure Egypt Hemato Oncology Testing Market Forecast (2019-2027)
Figure Nigeria Hemato Oncology Testing Market Forecast (2019-2027)
Figure South Africa Hemato Oncology Testing Market Forecast (2019-2027)
Figure Turkey Hemato Oncology Testing Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Hemato Oncology Testing Market Forecast (2019-2027)
Figure Global Hemato Oncology Testing Forecast by Type Of Cancer (2019-2027)
Figure Global Hemato Oncology Testing Market Share Forecast by Type Of Cancer (2019-2027)
Figure Global Hemato Oncology Testing Forecast by Type Of Cancer (2019-2027)
Figure Global Hemato Oncology Testing Forecast by Applications (2019-2027)
Figure Global Hemato Oncology Testing Market Share Forecast by Applications (2019-2027)
Figure Global Hemato Oncology Testing Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|